TAE Life Sciences (TLS) products

Gordon Locher first proposed Boron Neutron Capture Therapy (BNCT) in 1936. Clinical investigation and treatments were first introduced in the USA in the 1950s and showed promising results. Historically, BNCT clinical studies have been carried out using boronophenylalanine (BPA) and neutrons derived from the core of a nuclear reactor. While the clinical outcomes have been encouraging, the availability of better boron-10 compounds and access to a neutron source posed a significant barrier to clinical research and adoption of BNCT as a practical cancer therapy.

TAE Life Sciences is committed to developing a portfolio of novel targeted boron drugs to expand the application of BNCT to other cancer types and to provide even better outcomes for indications historically treated with Boronophenylalanine (BPA), a boron delivery drug.

TLS’s Alphabeam System includes a compact tandem accelerator-based neutron source and other hardware and software components to provide a complete BNCT solution. Our system is designed to be installed in a hospital setting and can be configured in a single or multi-room BNCT center to meet your clinical, research, and capacity needs. Treatment rooms includes fixed beam, beam shaping assembly, and a ceiling-mounted robotic couch for optimal patient positioning.